Novel Cancer Vaccine May Improve Survival in Synovial Sarcoma
Investigators are hopeful that CMB305, a vaccine that boosts the immune response to tumor cells expressing the antigen NY-ESO-1, can improve survival outcomes for patients with synovial sarcoma.
FDA Strategizes to Step Up Introduction of Lower-Cost Drugs and NGS
The market for biosimilar introduction is “extremely unstable,” but the FDA is working to ease the launch of more affordable cancer medicines with a strategy that includes an attempt to reduce anticompetitive behavior.
Study Explores ADT Alternative in Localized Prostate Cancer Recurrence
Cryoablation may help men whose prostate cancer recurs after radiation therapy avoid or delay retreatment with androgen deprivation therapy.
Adjuvant Chemotherapy Advances Boost Outcomes in GI Malignancies
Diane Reidy-Lagunes, MD, outlines the current state-of-the-art gastrointestinal care.
The ALK Story: Rapid Bench-to-Bedside Journey Helps Set New Pace for Cancer Drugs
Alice T. Shaw, MD, PhD, and D. Ross Camidge, MD, PhD, discuss the evolution of ALK-targeting therapies, the impact on the drug development paradigm, and the prospects for future advancements.
BET Inhibitors Form a Growing Area of Epigenetic Cancer Research
Rapid progress in the development of BET inhibitors has created a surge of enthusiasm.
Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.
Status Report: Expert Reviews Guideline-Based Options in Advanced CRC
There are pivotal developments in colorectal cancer that have shaped the National Comprehensive Cancer Network guidelines in the past several years.
Boom in Targeted Agents Propels AML Treatment Into a New Era of Personalized Care
During an OncLive Peer Exchange® a panel of AML experts discussed these newly approved agents and provided insight on how they are rapidly changing the standard of care for various AML subgroups.
CAR T-Cell Therapy: The Sticker Price Is Just for Openers
CMS has proposed a different way to handle payment for chimeric antigen receptor T-cell therapy, one that the medical and manufacturing community thinks is unworkable.
Genetic Cancer Risk Assessment: Highly Relevant But Increasingly Complex
Maurie Markman, MD, discusses the potential to employ germline data and knowledge about the presence of specific common, uncommon, or rare variants to cancer therapy.
It's Not Quite Prime Time for Up-Front Genomic Sequencing in Early-Stage CRC
Although testing for some genetic defects has been incorporated into the treatment paradigm, the clinical utility of up-front tumor sequencing that would yield wide-ranging information has not yet been established.
Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer
Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received
Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022
Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.